[Development of new antidiabetic drugs through the advanced knowledge of molecular biology in insulin signal transduction].
Kobayashi
Masashi
M
First Department of Medicine, Toyama Medical and Pharmaceutical University.
Hori
Hiroyuki
H
Kawahara
Junko
J
D000818:Animals; D001241:Aspirin; D015195:Drug Design; D007004:Hypoglycemic Agents; D007328:Insulin / Q000502:physiology*; D055504:Insulin Receptor Substrate Proteins; D000072183:Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; D010750:Phosphoproteins; D010744:Phosphoric Monoester Hydrolases; D010766:Phosphorylation; D017027:Protein Tyrosine Phosphatases; D011972:Receptor, Insulin; D012694:Serine; D015398:Signal Transduction; D013912:Threonine; D014409:Tumor Necrosis Factor-alpha
D007004:Hypoglycemic Agents; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; D010750:Phosphoproteins; D014409:Tumor Necrosis Factor-alpha; D013912:Threonine; D012694:Serine; D011972:Receptor, Insulin; D010744:Phosphoric Monoester Hydrolases; D017027:Protein Tyrosine Phosphatases; C098706:INPPL1 protein, human; D000072183:Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; D001241:Aspirin